<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04489290</url>
  </required_header>
  <id_info>
    <org_study_id>Piva01</org_study_id>
    <nct_id>NCT04489290</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of D005 Vaginal Mousse on Bacterial Vaginosis</brief_title>
  <official_title>A Randomised, Double-blind, and Placebo-controlled Post Market Clinical Follow-Up Investigation to Investigate the Clinical Performance of a Medical Device on Clinical Signs and Symptoms in Patients With Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmiva AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LINK Medical Research AB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CPS Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scandinavian Development Services AB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmiva AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind clinical investigation to evaluate the efficacy and safety&#xD;
      of D005 vaginal mousse compared to placebo, in women with bacterial vaginosis.&#xD;
&#xD;
      The study will be conducted at one site in Scotland, United Kingdom. The study population&#xD;
      will consist of approximately 96 female subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2021</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure rate</measure>
    <time_frame>23 to 28 days after last dosing</time_frame>
    <description>Clinical cure defined as absence of all of the following 3 Amsel criteria:&#xD;
Off-white (milky or gray), thin, homogeneous discharge.&#xD;
The presence of clue cells greater than 20% of the total epithelial cells on microscopic examination.&#xD;
A fishy odour (i.e., a positive whiff test) of the vaginal discharge with the addition of a drop of KOH.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical cure rate</measure>
    <time_frame>1 to 3 days after last dosing</time_frame>
    <description>Clinical cure defined as absence of all of the following 3 Amsel criteria:&#xD;
Off-white (milky or gray), thin, homogeneous discharge.&#xD;
The presence of clue cells greater than 20% of the total epithelial cells on microscopic examination.&#xD;
A fishy odour (i.e., a positive whiff test) of the vaginal discharge with the addition of a drop of KOH.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nugent score &lt;4</measure>
    <time_frame>1 to 3 days after last dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nugent score &lt;4</measure>
    <time_frame>23 to 28 days after last dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical cure + Nugent score &lt;4</measure>
    <time_frame>1 to 3 days after last dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical cure + Nugent score &lt;4</measure>
    <time_frame>23 to 28 days after last dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject-reported experiences and symptoms of vaginal malodour, discharge or itch during treatment</measure>
    <time_frame>1 to 3 days after last dosing</time_frame>
    <description>Vaginal malodour, discharge and itch will be graded as the following:&#xD;
Vaginal malodour 0 = normal, 1 = mild, 2 = moderate, 3 = severe Discharge 0 = normal, 1 = mild, 2 = moderate Itch 0 = normal, 1 = mild, 2 = moderate, 3 = severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject-reported experiences and symptoms of vaginal malodour, discharge or itch during treatment</measure>
    <time_frame>23 to 28 days after last dosing</time_frame>
    <description>Vaginal malodour, discharge and itch will be graded as the following:&#xD;
Vaginal malodour 0 = normal, 1 = mild, 2 = moderate, 3 = severe Discharge 0 = normal, 1 = mild, 2 = moderate Itch 0 = normal, 1 = mild, 2 = moderate, 3 = severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH of the vaginal fluid</measure>
    <time_frame>Day 1-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH of the vaginal fluid</measure>
    <time_frame>1 to 3 days after last dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH of the vaginal fluid</measure>
    <time_frame>23 to 28 days after last dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of clue cells</measure>
    <time_frame>1 to 3 days after last dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of clue cells</measure>
    <time_frame>23 to 28 days after last dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Bacterial Vaginoses</condition>
  <arm_group>
    <arm_group_label>D005 Vaginal Mousse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>D005 Vaginal Mousse</intervention_name>
    <description>D005 Vaginal Mousse is class IIa medical device for treatment of Bacterial Vaginosis.</description>
    <arm_group_label>D005 Vaginal Mousse</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willingness and ability to provide informed consent&#xD;
&#xD;
          2. Female in fertile age&#xD;
&#xD;
          3. Age ≥16 years&#xD;
&#xD;
          4. Nugent score ≥7&#xD;
&#xD;
          5. Bacterial vaginosis, as defined by the following criteria (Amsel criteria):&#xD;
&#xD;
               1. pH of vaginal fluid &gt;4.5&#xD;
&#xD;
               2. Positive amine test&#xD;
&#xD;
               3. Presence of clue cells&#xD;
&#xD;
               4. Presence of characteristic, homogenous vaginal discharge&#xD;
&#xD;
          6. Refrain from using any intravaginal products during the investigation period&#xD;
&#xD;
          7. Refrain from sexual intercourse during treatment. Refrain from sexual intercourse or&#xD;
             use a condom during rest of the investigation period to Visit 3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity or allergy to the investigational devices or to chemically related&#xD;
             products&#xD;
&#xD;
          2. Current use of an intrauterine device&#xD;
&#xD;
          3. Irregular menstruation cycle (21-35 days considered normal). Note that women with&#xD;
             amenorrhea are considered eligible.&#xD;
&#xD;
          4. Current pregnancy or intention to become pregnant within 1 month after treatment&#xD;
&#xD;
          5. Antibiotic treatment within 2 weeks before treatment&#xD;
&#xD;
          6. Signs of other infections (such as chlamydia, gonorrhoea, trichomonas, candida, HSV or&#xD;
             HPV) requiring specific antibiotic, antifungal or other treatment at screening.&#xD;
&#xD;
          7. Immunosuppression&#xD;
&#xD;
          8. Existing or suspected vaginal or cervical cancer or ulcer 9 Unprotected vaginal sex&#xD;
             within 24 hours prior to Visit 1&#xD;
&#xD;
        10. Be identified by the Investigator as inappropriate to participate in this investigation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CPS Research</name>
      <address>
        <city>Glasgow</city>
        <state>Scottland</state>
        <zip>G20 0XA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gordon Crawford, DR</last_name>
      <phone>+44 141 946 7888</phone>
      <email>gordon.crawford@cpsresearch.co.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 24, 2020</study_first_submitted>
  <study_first_submitted_qc>July 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

